Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: A systematic review

被引:6
作者
Das, Soumik [1 ]
Rajeswari, V. Devi [1 ]
Venkatraman, Ganesh [1 ]
Elumalai, Ramprasad [2 ]
Dhanasekaran, Sivaraman [3 ]
Ramanathan, Gnanasambandan [1 ]
机构
[1] Vellore Inst Technol VIT, Sch Biosci &Technol, Vellore 632014, Tamil Nadu, India
[2] Sri Ramachandra Inst Higher Educ & Res, Dept Nephrol, Chennai 600116, Tamil Nadu, India
[3] Pandit Deendayal Energy Univ, Sch Energy Technol, PDPU Rd, Gandhinagar 382426, Gujarat, India
关键词
Diabetic kidney disease; Metabolites; Gut microbiota; Pathway; Therapeutics; GLYCATION END-PRODUCTS; TRIMETHYLAMINE-N-OXIDE; P-CRESYL SULFATE; OXIDATIVE STRESS; RENAL-FUNCTION; NITRIC-OXIDE; HIGH GLUCOSE; GLYCEMIC CONTROL; NEPHROPATHY; GUT;
D O I
10.1016/j.trsl.2023.11.002
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Diabetic kidney disease (DKD) is a major microvascular complication of diabetes mellitus (DM) that poses a serious risk as it can lead to end -stage renal disease (ESRD). DKD is linked to changes in the diversity, composition, and functionality of the microbiota present in the gastrointestinal tract. The interplay between the gut microbiota and the host organism is primarily facilitated by metabolites generated by microbial metabolic processes from both dietary substrates and endogenous host compounds. The production of numerous metabolites by the gut microbiota is a crucial factor in the pathogenesis of DKD. However, a comprehensive understanding of the precise mechanisms by which gut microbiota and its metabolites contribute to the onset and progression of DKD remains incomplete. This review will provide a summary of the current scenario of metabolites in DKD and the impact of these metabolites on DKD progression. We will discuss in detail the primary and gut -derived metabolites in DKD, and the mechanisms of the metabolites involved in DKD progression. Further, we will address the importance of metabolomics in helping identify potential DKD markers. Furthermore, the possible therapeutic interventions and research gaps will be highlighted.
引用
收藏
页码:71 / 87
页数:17
相关论文
共 232 条
  • [1] Al-Hasani KKI, 2020, J EMJ, V5, P48
  • [2] Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
    Alicic, Radica Z.
    Johnson, Emily J.
    Tuttle, Katherine R.
    [J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2018, 25 (02) : 181 - 191
  • [3] Diabetic Kidney Disease Challenges, Progress, and Possibilities
    Alicic, Radica Z.
    Rooney, Michele T.
    Tuttle, Katherine R.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (12): : 2032 - 2045
  • [4] Standards of Medical Care in Diabetes-2014
    不详
    [J]. DIABETES CARE, 2014, 37 : S14 - S80
  • [5] Ana Merino-Ribas C., 2022, Human-Gut Microbiome: Establishment and Interactions: Developments in Microbiology, P233
  • [6] [Anonymous], 2023, Clinical Pharmacy Programs: UnitedHealthcare.
  • [7] [Anonymous], 2022, National diabetes statistics report, estimates of diabetes and its burden in the united states
  • [8] Metabolic signatures of insulin resistance in non-diabetic individuals
    Arjmand, Babak
    Fana, Saeed Ebrahimi
    Ghasemi, Erfan
    Kazemi, Ameneh
    Ghodssi-Ghassemabadi, Robabeh
    Dehghanbanadaki, Hojat
    Najjar, Niloufar
    Kakaii, Ardeshir
    Forouzanfar, Katayoon
    Nasli-Esfahani, Ensieh
    Farzadfar, Farshad
    Larijani, Bagher
    Razi, Farideh
    [J]. BMC ENDOCRINE DISORDERS, 2022, 22 (01)
  • [9] Colonic Contribution to Uremic Solutes
    Aronov, Pavel A.
    Luo, Frank J. -G.
    Plummer, Natalie S.
    Quan, Zhe
    Holmes, Susan
    Hostetter, Thomas H.
    Meyer, Timothy W.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (09): : 1769 - 1776
  • [10] Serum indoxyl sulfate levels in patients with diabetic nephropathy: Relation to renal function
    Atoh, Keita
    Itoh, Hiroshi
    Haneda, Masakazu
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 83 (02) : 220 - 226